Novartis, Anthos

Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion
The pharma giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to boost its cardiovascular pipeline.
Novartis buys back Anthos Therapeutics for up to $3.1B
Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement of regulatory and sales milestones. The transaction, which could reach $3.1 billion in total value, is expected to close in the early part of 2025.
Novartis Strikes Deal to Acquire Anthos Therapeutics
Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients with atrial fibrillation and cancer-associated thrombosis.
Novartis buys Blackstone's Anthos for up to $3.1 billion
(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost its cardiovascular business.
Novartis builds in cardiovascular with $3.1bn Anthos buy
Novartis has agreed to buy Anthos Therapeutics from private equity firm Blackstone for $3.1 billion, adding a drug in late-stage clinical testing to prevent complications in patients with atrial fibrillation (AF).
Novartis signs agreement to acquire Anthos for $925m upfront
Novartis has agreed to acquire Boston-based clinical-stage biopharmaceutical company Anthos Therapeutics for an upfront payment of $925m. The transaction includes $2.15bn of potential additional payments,
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 billion
Novartis to acquire Anthos Therapeutics for up to $3.1 billion
Swiss pharmaceutical company Novartis (SIX:NOVN) announced on Tuesday that it has entered into an agreement to purchase biopharma firm Anthos Therapeutics.
Novartis to buy Anthos Therapeutics for up to $3.1B
Novartis (NYSE:NVS) to acquire Anthos Therapeutics for a total deal value of up to $3.1B, consisting of an upfront payment of $925M, with potential additional payments of up to $2.15B. Anthos Therapeutics is a biopharmaceutical company founded in 2019 by Blackstone Life Sciences,
Novartis agrees to acquire Anthos for up to $3.1B
Novartis (NVS) announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held,
FierceBiotech2d
Novartis inks $925M Anthos takeover to buy back phase 3 clot-busting candidate
Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...
Novartis to pay $3.1B for Cambridge biotech led by former Karuna CEO
In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now ...
BioPharma Dive2d
Novartis pays $925M to reel in a startup it helped launch
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...
Pharmabiz2d
Novartis to buy Boston-based clinical-stage biopharma company, Anthos Therapeutics for up to $3.1 billion
Novartis to buy Boston-based clinical-stage biopharma company, Anthos Therapeutics for up to $3.1 billion: Basel Tuesday, February 11, 2025, 17:45 Hrs [IST] Novartis announced tha ...